Tiagabine

Lancet

Volumn 351, Issue 9097, 1998, Pages 203-207

  Leach, John Paul ^a   Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; NAPROXEN; SALICYLIC ACID; TIAGABINE; VALPROIC ACID;

4 AMINOBUTYRIC ACID UPTAKE; ASTHENIA; ATAXIA; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIARRHEA; DRUG EFFICACY; EPILEPSY; HEADACHE; HUMAN; META ANALYSIS; NERVOUSNESS; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; TREMOR; VERTIGO;

EID: 0032539470     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)05035-6     Document Type: Article

References (45)

1. 1 Sander JWAS, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996; 6: 433-43.
2. 2 Brodie MJ, Dichter M. Anticonvulsant drugs. N Engl J Med 1996; 334: 168-75.
3. 3 Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy - a reappraisal. CNS Drugs 1995; 3: 194-208.
4. 4 Brodie MJ. Antiepileptic drugs, clinical trials, and the marketplace. Lancet 1996; 347: 777-79.
5. 5 Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531-43.
6. 6 Wilson EA, Brodie MJ. New antiepileptic drugs. In: Brodie MJ, Treiman DM, eds. Modern management of epilepsy. Baillière's Clinical Neurology, Baillière-Tindall, London, 1996: 723-48.
7. 7 McKee PJW, Brodie MJ. Pharmacokinetic interactions with antiepileptic drugs. In: Trimble MR, ed. New anticonvulsants: advances in the treatment of epilepsy. Chichester: John Wiley, 1994: 1-33.
8. 8 Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996; 334: 1583-90.
9. 9 Brodie MJ, Richens A, Yuen AWC, et al. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476-79.
10. 10 Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy: a randomized, controlled study. Arch Neurol 1995; 52: 989-96.
11. 11 Leach JP, Brodie MJ. New antiepileptic drugs: an explosion of activity. Seizure 1995; 4: 5-17.
12. 12 Meldrum BS. Neurotransmission in epilepsy. Epilepsia 1995; 36 (suppl 1): S30-35.
13. 13 Petroff OAC, Rothman DL, Behar KL, Mattson RH. Low brain GABA level is associated with poor seizure control. Ann Neurol 1996; 40: 908-11.
14. 14 Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 1995; 36 (suppl 6): S7-9.
15. A receptor phramacology. Pharmacol Ther 1996; 173-98.
16. 16 Borden LA, Dhar TGM, Smith KE, Weinshank RL, Branchek TA, Gluchowski C. Tiagabine, SKF 89976-A, CI-966, and NNC-711 are selective for cloned GABA transporter GAT-1. Eur J Pharmacol 1994; 269: 219-24.
17. 17 Nielson EB, Suzdak PD, Andersen KE, Knutsen LJS, Sonnewald U, Braestrup C. Characterisation of tiagabine, a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991; 196: 257-66.
18. 18 Fink-Jensen A, Suzdak PD, Sweberg MDB, Judge ME, Hansen L, Nielsen PG. The GABA uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992; 220: 197-201.
19. 19 Clark JA, Amara SG. Stable expression of a neuronal γ-aminobutyric acid transporter, GAT-3, in mammalian cells demonstrates unique pharmacological properties and ion dependence. Mol Pharmacol 1994; 46: 550-57.
20. 20 Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995; 36: 612-26.
21. 21 Ostergaard LH, Gram L, Dam M. Potential antiepileptic drugs - tiagabine. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press. 1995: 1057-62.
22. 22 Leach JP, Sills GJ, Majid A, et al. Effect of tiagabine and vigabatrin on GABA uptake into primary cultures of rat cortical astrocytes. Seizure 1996; 5: 229-34.
23. 23 Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995; 36: 605-11.
24. 24 So EL, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995; 22: 221-26.
25. 14C] tiagabine in human hepatic microsomes. Epilepsia 1995; 36 (suppl 3): 159.
26. 26 Gustavson LE, Boellner SW, Granneman GR, et al. A single dose study to define tiagabine pharmacokinetics in paediatric patients with complex partial seizures. Neurology 1997; 48: 1032-37.
27. 27 Lau AH, Gustavson LE, Sperelakis R, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997; 38: 445-51.
28. 28 Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia 1995; 36; 14-21.
29. 29 Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995: 21: 37-42.
30. 30 Lassen LC. Phase II study of tiagabine. Copenhagen: Novo Nordisk report, 1994.
31. 31 Uthman B, Rowan AJ, Ahmann PA, et al. Multicenter randomised dose-response trial of tiagabine as adjunctive therapy with complex partial seizures. Arch Neurol (in press).
32. 32 Kälviäinen R, Brodie MJ, Chadwick D, et al. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Epilepsy Res (in press).
33. 33 Sachdeo R, Leroy R, Krauss G, et al. Tiagabine in complex partial seizures: a dose frequency study. Arch Neurol 1997; 54: 595-601.
34. 34 Brodie MJ. Tiagabine in the management of epilepsy. Epilepsia 1997; 38 (suppl 2): S23-27.
35. 35 Marson AG, Kadir AZ, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 13; 1169-74.
36. 36 Uldall P, Bulteau C, Pedersen SA, et al. Single-blind study of safety, tolerability and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy. Epilepsia 1995; 36 (suppl 3): S147-48.
37. 37 Schachter SC. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia 1995; 36 (suppl 6): S2-6.
38. 38 Schachter S, Biton V, Boellner S, et al. Safety and efficacy of tiagabine HCl monotherapy in the treatment of partial seizures: high dose versus low dose. Epilepsia 1995: 36 (suppl 3): 148.
39. 39 Biton V, Boellner S, Mercante D, Phillips H, Alto G, Sommerville K. Monotherapy with tiagabine in an open-label study of partial seizures. Epilepsia 1996; 37 (suppl 4): 40.
40. 40 Leppik IE. Tiagabine: the safety landscape. Epilespsia 1995; 36 (suppl 6): S10-13.
41. 41 Sveinbjornsdottir S, Sanders JWAS, Patsalos PN, Upton D, Thompson PJ, Duncan JS. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994; 3: 29-35.
42. 42 Kalviainen R, Aikia M, Mervaal E, Saukkonen AM, Pitkanen A, Riekkinen PJ. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res 1996; 25; 291-97.
43. 43 Dodrill CB, Arnett JL, Sommerville W, Shu V. Cognitive and quality of life effects of differing doses of tiagabine in epilepsy. Neurology 1997; 48; 1025-31.
44. 44 Leach JP, Stolarek I, Brodie MJ. Deliberate overdose with the novel anticonvulsant tiagabine. Seizure 1995; 4: 155-57.
45. 45 Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med 1994; 4: 141-50.